A Phase 1 interventional study of TQ-A3334 tablets and TQ-A3334 placebo tablets in Hepatitis B, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-30.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 192 studies in Hepatitis B with a site in China — 39 open to participants now, 49 under way, 1 of them phase 3. Hepatitis B · China.
Among the 192 studies in Hepatitis B with a site in China, this one is the 115th largest by enrollment of the 136 interventional ones that give a count, is one of 5 that started in 2023, is one of 19 in phase 1, and was the 161st registered.
1,047 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.
Browse Hepatitis B studies →39 of the 192 studies in Hepatitis B with a site in China are open now. Recruiting first, the newest first:
Jiyan Liu · Sites in China
Ages 18–65
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65
AusperBio Therapeutics Inc. · Sites in China, Australia, Japan and 4 more countries
Ages 18–65
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
192 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 38 · Phase 3 13 · Phase 4 43
First in 1983; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 145 across 757 interventional studies indexed under Hepatitis B.
Median enrollment 123 across the 136 interventional studies, 407 across the 53 observational. Of the 74 that completed or were terminated, 15 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 192 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chia Tai Tianqing Pharmaceutical Group Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
Sino Biopharmaceutical Limited has 1 study filed under Hepatitis B — fewer than ten, so there is no comparison to draw.
16 of the studies in Hepatitis B with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05453435Sun Yat-sen UniversityEntecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) | 2026-12 |
| NCT03826433Sclnow Biotechnology Co., Ltd.hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis | 2026-12-31 |
| NCT07240350Nanfang Hospital, Southern Medical UniversityThe Role and Regulatory Mechanism of Germinal Center Immune Response in Hepatitis B Virus Infection | 2026-12-31 |
| NCT07275554Qilu Hospital of Shandong UniversityAnalysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure | 2026-12-31 |
| NCT07413549Beijing Tuohua Weiye Biotechnology Co., Ltd.Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 192 studies in Hepatitis B with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blind, placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects, and the trial is planned to enroll 60 healthy subjects.
The primary objective is to evaluate the safety and tolerability of multiple dosing of TQ-A3334 tablets in healthy subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TQ-A3334 tablets, administered once a day.
Drug: TQ-A3334 tablets
TQ-A3334 placebo tablets, administered once a day.
Drug: TQ-A3334 placebo tablets
TQ-A3334 tablets, administered once every other day.
Drug: TQ-A3334 tablets
TQ-A3334 placebo tablets, administered once every other day.
Drug: TQ-A3334 placebo tablets
TQ-A3334 tablets, administered once every three days.
Drug: TQ-A3334 tablets
TQ-A3334 placebo tablets, administered once every three days.
Drug: TQ-A3334 placebo tablets
TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.
TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.
Incidence of adverse events (AE)
Incidence of adverse events (AE) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
Severity of adverse events (AE)
Severity of adverse events (AE) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
Incidence of serious adverse events (SAE)
Incidence of serious adverse events (SAE) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
Severity of serious adverse events (SAE)
Severity of serious adverse events (SAE) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
Tolerability after drug administration
Tolerability is evaluated by the number of participants with abnormal laboratory examinations, vital signs, physical examination, electrocardiogram.
Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
Peak Time (Tmax)
The time required to reach the highest concentration (peak drug concentration) on the human blood concentration curve after administration.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Peak concentration (Cmax)
The highest blood drug concentration achieved after administration.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Plasma concentration-area under time curve (AUC0-24)
The area under the plasma concentration-time curve from the beginning of the first administration to 24 hours.
Time frame: From 60 minutes before administration on Day 1 to 24 hours after the last administration.
Plasma concentration-area under time curve (AUC0-24)
The area under the plasma concentration-time curve from the beginning of the first administration to the last measurable concentration point.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Plasma concentration-area under time curve (AUC0-∞)
Extrapolated from the first administration to the area under the plasma concentration-time curve to infinity.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Apparent volume of distribution (Vd/F)
The ratio of the drug dosage in the body to the blood drug concentration when the drug reaches dynamic equilibrium in the body.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Clearance (CL/F)
Ratio of drug clearance rate to administration concentration.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Elimination half-life time (t1/2)
The time it takes to reduce the concentration of drugs in the blood by half
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Time of maximum concentration under steady state (Tmax,ss)
Time required to reach steady-state peak concentration after administration.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Maximum concentration under steady state (Cmax, ss)
The highest blood drug concentration that occurs after reaching steady state.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Minimum concentration under steady state (Cmin, ss)
The lowest blood drug concentration that occurs after reaching steady state.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Plasma concentration at steady state (Cav, SS)
The plasma concentration at which the rate of administration and rate of elimination are in equilibrium.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Plasma concentration area under steady-state time curve (AUCss)
The area under the plasma concentration-time curve of the steady state.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Accumulation Index (Rac)
The ratio of steady-state blood drug concentration to blood drug concentration after the first administration.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Degree of fluctuation (DF)
The ratio of the difference between the maximum steady-state blood drug concentration and the minimum steady-state blood drug concentration to the average steady-state blood drug concentration.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Interferon-α concentration (IFN-α)
The change of subjects' blood IFN-α concentration from baseline.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Interferon-stimulated gene concentration (ISG)
The change of subjects' blood ISG concentration from baseline.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Interferon-gamma concentration (IFN-γ)
The change of subjects' blood IFN-γ concentration from baseline.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Tumor Necrosis Factor-α concentration (TNF-α)
The change of subjects' blood TNF-α concentration from baseline.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Interleukin-6 concentration (IL-6)
The change of subjects' blood IL-6 concentration from baseline.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Interleukin-2 concentration (IL-2)
The change of subjects' blood IL-2 concentration from baseline.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Monocyte Chemotactic Protein 1 concentration (MCP-1)
The change of subjects' blood MCP-1 concentration from baseline.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Interferon-inducible protein-10 concentration (IP-10)
The change of subjects' blood IP-10 concentration from baseline.
Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.
QT/QT interval
Level of change in QT/QT interval to evaluate the drug cardiotoxicity.
Time frame: From 30 minutes before administration on Day 1 to 48 hours after the last administration.
Ran from Dec 2023 to primary completion in Jun 2024, 5 months.
Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 5 months is below that.
Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TLR7 Agonist JNJ-64794964
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →